1. Clinical Overview
Darbepoetin alfa is a recombinant erythropoiesis-stimulating agent (ESA) with a longer half-life than endogenous erythropoietin or recombinant epoetin. It is a hyperglycosylated analog of human erythropoietin, created by site-directed mutagenesis to introduce two additional N-linked carbohydrate chains. This modification enhances its metabolic stability, allowing for less frequent dosing. It is used to treat anemia by stimulating red blood cell production in the bone marrow.
| Onset | Duration | Bioavailability |
|---|---|---|
| Significant increase in reticulocyte count is typically observed within 7-10 days. A clinically significant rise in hemoglobin (Hb) usually takes 2-6 weeks. | The pharmacodynamic effect (increased Hb) persists for the duration of treatment. The extended half-life allows for dosing intervals of once weekly or once every two to three weeks, depending on the indication and route. | Approximately 37% following subcutaneous administration. Bioavailability after intravenous administration is 100%. |
2. Mechanism of Action
Darbepoetin alfa binds to the erythropoietin receptor (EpoR) on the surface of erythroid progenitor cells in the bone marrow, primarily colony-forming unit-erythroid (CFU-E) cells. This binding activates the JAK2/STAT5 intracellular signaling pathway, promoting the proliferation, differentiation, and survival of these progenitor cells, leading to increased production of reticulocytes and mature red blood cells.
3. Indications & Uses
- Anemia associated with Chronic Kidney Disease (CKD) in both dialysis and non-dialysis patients.
- Chemotherapy-Induced Anemia (CIA) in adult patients with non-myeloid malignancies receiving chemotherapy.
4. Dosage & Administration
Adult Dosage: CKD: Initial SC dose: 0.45 mcg/kg once weekly OR 0.75 mcg/kg once every 2 weeks. Adjust to maintain Hb ≤12 g/dL. CIA: Initial SC dose: 2.25 mcg/kg once weekly OR 500 mcg once every 3 weeks. Adjust to maintain Hb ≤12 g/dL.
Administration: For subcutaneous use: Administer in the abdomen, thigh, or upper arm. Rotate injection sites. Do not shake the vial/pre-filled syringe. Visually inspect for particulate matter or discoloration before use. The 40 mcg strength is typically available as a single-dose pre-filled syringe or vial. Discard any unused portion.
5. Side Effects
Common side effects may include:
- Hypertension
- Headache
- Arthralgia (joint pain)
- Injection site pain/erythema
- Nausea
- Edema (peripheral edema)
- Fatigue
- Pyrexia (fever)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Heparin | Increased risk of bleeding if administered through an IV line containing heparin. Use separate lines. | Moderate |
| Cyclosporine, Tacrolimus | Theoretical risk of increased immunogenicity. Monitor drug levels of immunosuppressants. | Low |
| Iron supplements | Concomitant use is essential for an optimal hematopoietic response. Functional iron deficiency can limit efficacy. | Beneficial Interaction |
7. Patient Counselling
- DO have your blood pressure checked regularly as directed.
- DO get your hemoglobin checked regularly before each dose adjustment.
- DO inform all your doctors and surgeons that you are taking this medication.
- DO ensure adequate iron intake (supplements as prescribed).
- DO NOT exceed the prescribed dose or frequency.
- DO NOT use if you are pregnant or planning pregnancy without discussing with your doctor.
- DO NOT shake the medication; handle pre-filled syringes gently.
8. Toxicology & Storage
Overdose: Polycythemia (excessively high hemoglobin/hematocrit), which can lead to hypertension, headache, dizziness, thrombotic events (stroke, MI, DVT), and potentially hypertensive encephalopathy with seizures.
Storage: Store at 2°C to 8°C (in a refrigerator). Do not freeze. Protect from light. Do not shake. Keep in the outer carton. For the pre-filled syringe: Once removed from the refrigerator, the product may be stored at room temperature (not above 25°C) for a single period of up to 7 days. Do not re-refrigerate. Discard any unused product after this period or after the expiry date, whichever is earlier.